Dr Mehra on the Evolution of HPV-Related Head and Neck Cancer Management | OncLive Ranee Mehra, MD, highlights developments and ongoing questions regarding the evolving treatment paradigm for patients with head and neck cancer.

WATCH 👀: Ranee Mehra, MD, highlights developments and ongoing questions regarding the evolving treatment paradigm for patients with head and neck cancer.

See the whole video here 📷: www.onclive.com/view/dr-mehr...

#hncsm #oncology

Dr Mehra on the Design of the OrigAMI-5 Trial of Amivantamab-Based Therapy in HNSCC | OncLive Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC.

WATCH: Ranee Mehra, MD, highlights how the ongoing OrigAMI-5 study may address an unmet need for patients with treatment-naive, recurrent or metastatic HNSCC. #hncsm #oncology
www.onclive.com/view/dr-mehr...

📹Watch Ranee Mehra, MD, highlight the future of the HNSCC treatment paradigm! See our site for more head and neck cancer insights from Dr Mehra. #hncsm #oncology
www.onclive.com/video-series...

Dr Mehra on the Use of Amivantamab Plus Pembrolizumab and Carboplatin in HNSCC | OncLive Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC.

WATCH: Ranee Mehra, MD, discusses the design of the OrigAMI-5 trial of pembrolizumab plus amivantamab and carboplatin for recurrent or metastatic HNSCC. #hncsm #oncology
www.onclive.com/view/dr-mehr...

Dr Mehra on the Safety Profile of Subcutaneous Amivantamab in HNSCC | OncLive Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC.

WATCH: Ranee Mehra, MD, discusses the toxicities associated with subcutaneous amivantamab in recurrent or metastatic HNSCC. #hncsm #Oncology www.onclive.com/view/dr-mehr...

Dr Mehra on the Efficacy of Subcutaneous Amivantamab Plus Pembrolizumab in HNSCC | OncLive Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC.

WATCH: Ranee Mehra, MD, discusses the efficacy of subcutaneous amivantamab plus pembrolizumab in patients with first-line recurrent or metastatic HNSCC. #hncsm #oncology
www.onclive.com/view/dr-mehr...

Dr Mehra on the FDA Breakthrough Therapy Designation for Amivantamab in HNSCC | OncLive Ranee Mehra, MD, discussed the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC.

WATCH: Ranee Mehra, MD, discussed the FDA breakthrough therapy designation for amivantamab and hyaluronidase for patients with recurrent or metastatic HNSCC. #hncsm #oncology
www.onclive.com/view/dr-mehr...

FDA Grants Fast Track Status to BNT113 for HPV16+ Head and Neck Cancer - Oncology Nurse Advisor The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.

The @fda.gov has granted Fast Track designation to BNT113 for the treatment of HPV16+ #headandNeckSquamousCellCarcinoma expressing PD-L1. From @medicalprofref.bsky.social.

https://bit.ly/469qyXr

#HNSCC #hncsm

IMPT Delivers Superior OS, Less High-Grade Toxicity in Oropharyngeal Cancer - Oncology Nurse Advisor Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation

IMPT improves OS and reduces high-grade toxicity compared with IMRT for adults with #oropharyngealCancer. Published in @thelancet.com and @cancertherapyadv.bsky.social.

https://bit.ly/4jBjWXm

#hncsm #headandneckcancer

IMPT Delivers Superior OS, Less High-Grade Toxicity in Oropharyngeal Cancer Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation

IMPT improves OS and reduces high-grade toxicity compared with IMRT for adults with #oropharyngealCancer. Published in @thelancet.com.

https://bit.ly/4pC7jwQ

#hncsm

Joint Study Finds Proton Beam Therapy Helps Patients With Throat Cancer Live Longer With Fewer Side Effects | OncLive Proton beam therapies can result in strong outcomes for patients with throat cancer according to Mayo Clinic researchers.

Joint Study Finds Proton Beam Therapy Helps Patients With Throat Cancer Live Longer With Fewer Side Effects
@mayocliniccancer.bsky.social #hncsm #oncology
www.onclive.com/view/joint-s...

Artificial Neural Networks Offer Promise as Prognostic Tool for Older Adults with HNSCC Researchers sought to develop and validate artificial neural networks for overall survival and progression-free survival in older adults with HNSCC following definitive chemoradiation.

Artificial neural networks delivered accurate prognostic information for older adults with #headandNeckSquamousCellCarcinoma using routine clinical data. Published in @jamaotolaryngology.com.

https://bit.ly/4rmTN1Q

#HNSCC #hncsm

Dr Barbara Burtness's Key Takeaways in Head and Neck Cancer from ESMO Congress 2025 Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

Dr Burtness shares some of her key takeaways in #headandNeckCancer from @myesmo.bsky.social #ESMO2025.

https://bit.ly/48j1vTk

#hncsm #HNC

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC | OncLive Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC @upmc.com #hncsm #oncology
www.onclive.com/view/post-op...

Adding Nimotuzumab to Chemoradiotherapy Does Not Improve Survival in HNSCC - Oncology Nurse Advisor “latinum-based chemoradiotherapy is a hard combo to beat,” said N. Gopalakrishna Iyer, MBBS, PhD, noting that the researchers were “quite surprised” by the overall survival achieved in the control arm, given the real-world setting of the trial.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with #HNSCC. Presented at #ESMO25.

https://bit.ly/47oCYMb

#hncsm #headandneckcancer

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC | OncLive The European Commission approved perioperative pembrolizumab plus adjuvant radiotherapy with or without cisplatin in resectable locally advanced HNSCC.

Pembrolizumab-Based Combo Wins EU Approval for PD-L1+ Resectable Locally Advanced HNSCC #hncsm #oncology
www.onclive.com/view/pembrol...

Sequencing IO and radiotherapy in nasopharyngeal carcinoma - VJOncology Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the potential benefits of integrating PD-1 immunotherapy (IO)...

🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses sequencing IO and radiotherapy in nasopharyngeal carcinoma:

➡️ buff.ly/K24ba3d ⬅️

#ASCO25 #ImmunOnc #hncSM

ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC | OncLive The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.

ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC @myesmo.bsky.social #ESMO2025 #ESMO25 #hncsm #oncology
www.onclive.com/view/adc-iza...

Administering durvalumab before and after CRT did not provide a benefit over CRT alone in a phase 3 trial of patients with intermediate- and high-risk oropharyngeal cancer. Presented at #ESMO25 by Dr Hisham Mehanna of @unibirmingham.bsky.social. #hncsm #esmo2025

shorturl.at/ADTqx

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC, according to research presented at #ESMO25 by Dr N. Gopalakrishna Iyer of the National Cancer Centre Singapore. #hncsm #esmo2025

shorturl.at/ee5iI

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology | OncLive Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology #bcsm #scmsm #hncsm
www.onclive.com/view/onclive...

FDA Removes REMS Program for Vandetanib for Medullary Thyroid Cancer | OncLive The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.

FDA Removes REMS Program for Vandetanib for Medullary Thyroid Cancer @fda.gov #hncsm #oncology
www.onclive.com/view/fda-rem...

FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC | OncLive The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC
@fda.gov #HeadandNeckCancer #HNSCC #hncsm
www.onclive.com/view/fda-gra...

HPV isn’t just linked to cervical cancer.

During Head & Neck Cancer Awareness Week, starting today, let’s spread the word about the value of vaccinating everyone to protect them against all the cancers caused by HPV. 💉

🔗 makesensecampaign.eu/en/

#HNCSM

Tobacco use is a major risk factor for head and neck cancers. 🛑

Take a look at this powerful infographic from the #MakeSenseCampaign and spread the word: knowing your risks can save lives. 📊

🔗 makesensecampaign.eu/en/

#HNCSM

FDA Provides Guidance on Registrational Path for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma The FDA has provided guidance on the design of a potential phase 3 trial evaluating the ADC ozuriftamab vedotin in OPSCC.

FDA Provides Guidance on Registrational Path for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma
@fda.gov #OropharyngealCancer #HNCSM
www.onclive.com/view/fda-pro...

Shorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study Shows A shorter and less intense course of postoperative radiation plus chemotherapy was shown to be effective in HPV-positive oropharyngeal cancer.

Shorter, Less Intense Radiation-Chemo Regimen Effective for HPV-Linked Oropharyngeal Cancer, Mayo Study Shows
@mayoclinic.org #OropharyngealCancer #hncsm
www.onclive.com/view/shorter...

From 15-20 September, we mark Head & Neck Cancer Awareness Week, a vital moment to raise awareness of a disease that remains under-recognised, yet life-threatening when detected late.

More info at: makesensecampaign.eu/en/

#HNCSM #MakeSenseCampaign

Upright Proton Therapy Deemed Promising for Head and Neck, Brain Cancer The “early promising clinical outcomes” provide a strong basis for further investigation of upright image-guided adaptive proton therapy, according to researchers.

IGAPT administered to patients in an upright position appears to be a safe and effective treatment approach for recurrent #headandNeckCancer or #braincancer, according to researchers.

https://bit.ly/4lSl8Fn

#hncsm

First-in-Concept ADC Micvotabart Pelidotin Shows Early Antitumor Activity in HNSCC Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

First-in-Concept ADC Micvotabart Pelidotin Shows Early Antitumor Activity in HNSCC @danafarber.bsky.social @harvardmed.bsky.social #hncsm #oncology
www.onclive.com/view/first-i...